Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Metastasis | Research article

MiR-105-3p acts as an oncogene to promote the proliferation and metastasis of breast cancer cells by targeting GOLIM4

Authors: Bo Lin, Chunhua Liu, Enyi Shi, Qiu Jin, Wenhui Zhao, Juan Wang, Runyuan Ji

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Dysregulated miRNAs are involved in carcinogenesis of the breast and may be used as prognostic biomarkers and therapeutic targets during the cancer process. The purpose of this study was to explore the effect of miR-105-3p on the tumourigenicity of breast cancer and its underlying molecular mechanisms.

Methods

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was applied to detect the expression of miR-105-3p in breast cancer tissues and cell lines. The impacts of miR-105-3p on the proliferation, migration, invasion and apoptosis of human breast cancer cells (MCF-7 and ZR-75-30) were evaluated by CCK-8 assays, Transwell chamber assays, TUNEL assays and western blot analyses. In addition, bioinformatics and luciferase reporter assays were used to determine the target genes of miR-105-3p.

Results

The expression of miR-105-3p was elevated in breast cancer tissues and increased with tumour severity. Downregulation of miR-105-3p could inhibit cell proliferation, suppress cell migration/invasion, and promote cell apoptosis in MCF-7 and ZR-75-30 cells. Furthermore, Golgi integral membrane protein 4 (GOLIM4) was identified as the direct target gene of miR-105-3p by bioinformatics and luciferase reporter assays. In addition, silencing GOLIM4 restored the anti-breast cancer effects induced by miR-105-3p downregulation.

Conclusions

MiR-105-3p acts as an oncogene to promote the proliferation and metastasis of breast cancer cells by targeting GOLIM4, which provides a new target for the prevention and treatment of breast cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Anastasiadi Z, et al. Breast cancer in young women: an overview. Updat Surg. 2017;69(3):313–7.CrossRef Anastasiadi Z, et al. Breast cancer in young women: an overview. Updat Surg. 2017;69(3):313–7.CrossRef
2.
3.
go back to reference Li T, Mello-Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Cancer Res Treat. 2016;159(3):395–406.CrossRef Li T, Mello-Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Cancer Res Treat. 2016;159(3):395–406.CrossRef
4.
go back to reference Waks AG, Winer EP. Breast Cancer treatment: a review. JAMA. 2019;321(3):288–300.CrossRef Waks AG, Winer EP. Breast Cancer treatment: a review. JAMA. 2019;321(3):288–300.CrossRef
5.
go back to reference Qadir MI, Faheem A. miRNA: a diagnostic and therapeutic tool for pancreatic Cancer. Crit Rev Eukaryot Gene Expr. 2017;27(3):197–204.CrossRef Qadir MI, Faheem A. miRNA: a diagnostic and therapeutic tool for pancreatic Cancer. Crit Rev Eukaryot Gene Expr. 2017;27(3):197–204.CrossRef
6.
go back to reference Sun Z, et al. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018;17(1):147.CrossRef Sun Z, et al. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018;17(1):147.CrossRef
7.
go back to reference Vishnoi A, Rani S. MiRNA Biogenesis and Regulation of Diseases: An Overview. Methods Mol Biol. 2017;1509:1–10.CrossRef Vishnoi A, Rani S. MiRNA Biogenesis and Regulation of Diseases: An Overview. Methods Mol Biol. 2017;1509:1–10.CrossRef
8.
go back to reference Zou Q, et al. MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1. Exp Ther Med. 2017;14(2):1009–16.CrossRef Zou Q, et al. MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1. Exp Ther Med. 2017;14(2):1009–16.CrossRef
9.
go back to reference Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther. 2017;172:34–49.CrossRef Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther. 2017;172:34–49.CrossRef
10.
go back to reference Bahena-Ocampo I, et al. miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation. EMBO Rep. 2016;17(7):1081.CrossRef Bahena-Ocampo I, et al. miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation. EMBO Rep. 2016;17(7):1081.CrossRef
11.
go back to reference Damiano V, et al. Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1. Genes chromosomes cancer. 2017;56(2):147–58.CrossRef Damiano V, et al. Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1. Genes chromosomes cancer. 2017;56(2):147–58.CrossRef
12.
go back to reference Shen G, et al. MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma. Carcinogenesis. 2014;35(12):2748–55.CrossRef Shen G, et al. MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma. Carcinogenesis. 2014;35(12):2748–55.CrossRef
13.
go back to reference Sirotkin AV, et al. Identification of microRNAs controlling human ovarian cell proliferation and apoptosis. J Cell Physiol. 2010;223(1):49–56.PubMed Sirotkin AV, et al. Identification of microRNAs controlling human ovarian cell proliferation and apoptosis. J Cell Physiol. 2010;223(1):49–56.PubMed
14.
go back to reference Merino Bonilla JA, Tabanera MT, Mendoza LHR. Breast cancer in the 21st century: from early detection to new therapies. Radiologia. 2017;59(5):368–79.CrossRef Merino Bonilla JA, Tabanera MT, Mendoza LHR. Breast cancer in the 21st century: from early detection to new therapies. Radiologia. 2017;59(5):368–79.CrossRef
15.
go back to reference Inns J, James V. Circulating microRNAs for the prediction of metastasis in breast cancer patients diagnosed with early stage disease. Breast. 2015;24(4):364–9.CrossRef Inns J, James V. Circulating microRNAs for the prediction of metastasis in breast cancer patients diagnosed with early stage disease. Breast. 2015;24(4):364–9.CrossRef
16.
go back to reference Serpico D, Molino L, Di Cosimo S. microRNAs in breast cancer development and treatment. Cancer Treat Rev. 2014;40(5):595–604.CrossRef Serpico D, Molino L, Di Cosimo S. microRNAs in breast cancer development and treatment. Cancer Treat Rev. 2014;40(5):595–604.CrossRef
17.
go back to reference Gao R, et al. MicroRNA-105 plays an independent prognostic role in esophageal cancer and acts as an oncogene. Cancer Biomark. 2020;27(2):173–80.CrossRef Gao R, et al. MicroRNA-105 plays an independent prognostic role in esophageal cancer and acts as an oncogene. Cancer Biomark. 2020;27(2):173–80.CrossRef
18.
go back to reference Li HY, et al. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Res. 2017;19(1):133.CrossRef Li HY, et al. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Res. 2017;19(1):133.CrossRef
19.
go back to reference Shen Z, et al. MicroRNA-105 is involved in TNF-alpha-related tumor microenvironment enhanced colorectal cancer progression. Cell Death Dis. 2017;8(12):3213.CrossRef Shen Z, et al. MicroRNA-105 is involved in TNF-alpha-related tumor microenvironment enhanced colorectal cancer progression. Cell Death Dis. 2017;8(12):3213.CrossRef
20.
go back to reference Witkos TM, Lowe M. Recognition and tethering of transport vesicles at the Golgi apparatus. Curr Opin Cell Biol. 2017;47:16–23.CrossRef Witkos TM, Lowe M. Recognition and tethering of transport vesicles at the Golgi apparatus. Curr Opin Cell Biol. 2017;47:16–23.CrossRef
21.
go back to reference Bai Y, et al. Golgi integral membrane protein 4 manipulates cellular proliferation, apoptosis, and cell cycle in human head and neck cancer. Biosci Rep. 2018;38(4):BSR20180454.CrossRef Bai Y, et al. Golgi integral membrane protein 4 manipulates cellular proliferation, apoptosis, and cell cycle in human head and neck cancer. Biosci Rep. 2018;38(4):BSR20180454.CrossRef
22.
go back to reference Ivanova AV, et al. Loss of PL6 protein expression in renal clear cell carcinomas and other VHL-deficient tumours. J Pathol. 2008;214(1):46–57.CrossRef Ivanova AV, et al. Loss of PL6 protein expression in renal clear cell carcinomas and other VHL-deficient tumours. J Pathol. 2008;214(1):46–57.CrossRef
Metadata
Title
MiR-105-3p acts as an oncogene to promote the proliferation and metastasis of breast cancer cells by targeting GOLIM4
Authors
Bo Lin
Chunhua Liu
Enyi Shi
Qiu Jin
Wenhui Zhao
Juan Wang
Runyuan Ji
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-07909-2

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine